Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (<scp>PR</scp>) Compared with Oxycodone/Naloxone <scp>PR</scp> in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open‐label, Phase 3b/4 Trial

Abstract

Tapentadol PR had a minimal impact on bowel function (noninferior to oxycodone/naloxone PR) and, along with superior effectiveness (presented separately), was associated with significantly lower incidences of constipation and vomiting and significant improvements in quality-of-life measures vs. oxycodone/naloxone PR.